{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-222892","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2026-05-14T12:15:18+00:00","discovered_at":"2026-05-14T12:20:00.440663+00:00","generated_at":"2026-05-14T12:22:03.303651+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Candel Therapeutics Q1 2026 net loss $8.9M; BLA submission for CAN-2409 on track for Q4 2026","bullets":["Net loss of $8.9M in Q1 2026 vs net income $7.4M in Q1 2025; R&D expense $9.8M.","Cash and equivalents $194.8M as of March 31, 2026, expected to fund operations into Q1 2028.","Plans to submit BLA for aglatimagene (CAN-2409) in localized prostate cancer in Q4 2026.","Extended follow-up from Phase 2a NSCLC trial shows 50% of patients survived >24 months; Phase 3 NSCLC trial to start June 2026.","Announced commercial partnership with EVERSANA and $100M royalty funding agreement with RTW for potential launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-222892","json":"https://secwatch.observer/filing/0001193125-26-222892.json","markdown":"https://secwatch.observer/filing/0001193125-26-222892.md","text":"https://secwatch.observer/filing/0001193125-26-222892.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526222892/0001193125-26-222892-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526222892/cadl-20260514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T12:22:03.303651+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c096c2f42a92858168965e63d46d37e3047aa9be","claim":"Candel Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"On May 14, 2026, Candel Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000119312526222892/0001193125-26-222892-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}